申请人:Bristol-Myers Company
公开号:EP0111397A1
公开(公告)日:1984-06-20
Novel phthalimide intermediates are reduced to 5-sulfamoyl-6-halo-3-oxoisoindole compounds bearing a substituted 1-phenylalkyl-4-piperidinyl moiety as the isoindole N-substitutent. Preferred compounds such as 6-chloro-2,3-dihydro-3-oxo-2-[1-(phenylmethyl)-4-piperidinyl]-1H-isoindole-5-sulfonamide exhibit diuretic and antihypertensive properties.
新颖的邻苯二甲酰亚胺中间体被还原成 5-氨基磺酰基-6-卤-3-氧代异吲哚化合物,该化合物以取代的 1-苯基烷基-4-哌啶基为异吲哚 N-取代基。 首选化合物如 6-氯-2,3-二氢-3-氧代-2-[1-(苯基甲基)-4-哌啶基]-1H-异吲哚-5-磺酰胺具有利尿和降压特性。